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The y-subspecies of protein kinase C (PKC) apparently is expressed only in central nervous tissues, and at a high level 
in the cerebellum and hippocampus. ?-PKC from bovine cerebellum, but not the ~t- or fll/flII-subspecies, is activated by 
micromolar concentrations of arachidonic acid (AA), in the absence of both phospholipid and diacylglycerol. A signifi- 
cant component of this activation isalso calcium independent. Other unsaturated fatty acids are much less active in this 
respect. Among the AA metabolites tested, lipoxin A (5(S),6(R),15(S)-1 l-c/s-isomer) was a potent, selective activator of 
the y-subspecies, and also, to a lesser extent, 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid ould support activation. 
These results raise the possibility that AA and some of its lipoxygenase metabolites may function as messenger molecules 
in neurones to activate the ~,-subspecies of PKC. 
Protein kinase C; Arachidonic acid; Lipoxygenase metabolite 
1. INTRODUCTION 
Molecular cloning analysis has revealed the ex- 
istence of multiple PKC subspecies in mammalian 
brain tissue, that can be provisionally divided into 
two groups (a/~I/BII/7 and 3/e/~') on the basis of 
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their structural characteristics (see [1] for a review 
and references). The PKC enzyme molecules en- 
coded by the or-, g/l-, BII- and 7-sequences have 
been purified from rat whole brain tissue and 
resolved into three distinct fractions by hydrox- 
yapatite chromatography, the identities of which 
have been established as type I(7), type II(flI/BII) 
and type III(c0 [2-5]. The 7-subspecies ofPKC ap- 
pears to be expressed only in central nervous tissue 
areas [6], and is present at a high level in the 
cerebellum and hippocampus [7,8]. 
Immunohistochemical analysis with subspecies- 
specific monoclonal ntibodies has shown this en- 
zyme to be confined to cerebellar Purkinje cells 
[5,9,10], where it is present in the dendrites, cell 
soma, axons and synaptic terminals [9,11]. In con- 
trast, in the same tissue, •I-PKC is present in the 
granule cell soma, and BII-PKC is present in the 
molecular layer, seemingly associated with pre- 
synaptic terminals terminating on Purkinje cell 
dendrites [10]. a,-PKC may be present in both 
Purkinje and granule cells [5]. Such a defined cell- 
specific expression of PKC subspecies prompted us 
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to invest igate their  potent ia l  roles in neurona l  
t ransmiss ion  in the cerebel lum.  As an init ial step, 
we have pur i f ied and reso lved the ind iv idual  
subspecies f rom bov ine  cerebe l lum in order  to 
character ize  their  enzymolog ica l  propert ies ,  and 
repor t  here their  sensit iv ity to act ivat ion by AA 
and its metabol i tes .  
2. MATERIALS  AND METHODS 
2.1. Materials and chemicals 
PtdSer, DO, AA and oleic acid were purchased from Serdary 
Research Laboratories. AA was also obtained from Nu-Check- 
Prep. Other fatty acids were generous gifts from Drs S. Satoh 
and Y. Nakano (Nippon Oil & Fats Company). AA metabolites 
were a generous gift from Dr S. Yamamoto (Tokushima 
University, Japan), and in addition, a batch of LxA was most 
kindly supplied by Dr J. Rokach (Merck Frosst Canada Inc.). 
[~)2p]ATP was purchased from Amersham. 
2.2. Preparation of PKC subspecies from bovine cerebellum 
PKC subspecies were purified from freshly obtained bovine 
cerebellum soluble and particulate fractions, by DEAE- 
cellulose, threonine-Sepharose, TSK gel phenyl-SPW and 
G3000SW column chromatographies, sentially as described 
for rat whole brain [12]. All procedures were carried out at 4°C. 
The buffer system used was 20 mM Tris-HC1 (pH 7.5) contain- 
ing 0.5 mM EGTA, 0.5 mM EDTA and 10 mM 2-mercapto- 
ethanol (buffer A), to which the appropriate concentrations of 
NaCl were added. The purified mixture of PKC subspecies was 
then resolved by loading the sample onto a packed hydroxy- 
apatite column (1.07 cm × 10 cm, Type S, Koken Ltd, Tokyo), 
coupled to an FPLC system (Pharmacia), that was equilibrated 
with 20 mM potassium phosphate buffer (pH 7.5), containing 
0.5 mM EGTA, 0.5 mM EDTA, 10 mM 2-mercaptoethanol 
and 10% (v/v) glycerol (buffer B). The type I(7), type lI(fll/BII) 
and type III(tr) enzyme subspecies were then separately eluted 
by the application of a linear concentration gradient of 
potassium phosphate (20 mM to 215 mM) in 135 ml of buffer 
B, at a flow rate of 0.75 ml/min. Fractions comprising the three 
separate peaks of enzyme activity were pooled, dialyzed against 
buffer A containing 10% (v/v) glycerol, and stored at - 80°C 
until use. 
2.3. Assay of PKC activity 
Enzyme activity was assayed at 30°C by measuring the incor- 
poration of 32Pi nto H 1 histone from [T)2P]ATP, as previous- 
ly described [7]. To the standard reaction mixture were added 
8/~g/ml PtdSer and 0.8/~g/ml DO or test compounds, calcium 
chloride or EGTA (as indicated) and 20/~1 enzyme fraction 
(final assay volume 0.25 ml). PtdSer/DO, fatty acids or AA 
metabolites, were prepared by firstly, drying down aliquots of 
the stock solutions (stored either at -20°C or -80°C) under 
N2, and then resuspension i 20 mM Tris-HC1 (pH 7.5) by 
vortexing and sonication on ice (3 x 1 min). For LxA, 20 mM 
Tris-HC1 containing 5% (v/v) methanol was used. This concen- 
tration of solvent had no effect on PKC activity. Each concen- 
tration of compound was prepared separately (as opposed to 
dilution after sonication), and added immediately prior to the 
start of the assay. 
3. RESULTS 
3.1. Properties o f  PKC subspecies 
PKC act iv i ty f rom bov ine  cerebe l lum can be 
reso lved into three dist inct  f ract ions by hydrox-  
yapat i te  co lumn chromatography  ( f ig . lA ) .  The  
re lat ive e lut ion pos i t ion o f  these subspecies,  their  
mode o f  act ivat ion,  b iochemica l  propert ies ,  and 
immunob lo t t ing  analysis wi th subspecies-speci f ic  
monoc lona l  and po lyc lona l  ant ibodies ,  have col-  
lect ively establ ished the ident i ty  o f  the three peaks 
as cor respond ing  to type I(7), type I I (~' I /~I I )  and 
type I I I (a )  PKC subspecies,  respect ively.  As 
prev ious ly  descr ibed for  rat and monkey  t issue 
[7,8], cerebe l lum is a r ich source for  the T-type en- 
mv ~ 4o 
I o 
~ m 
T ~ T - - T  .T  
.A 
t 6 s 4 3 t 6 5 4 a t 6 s 4 3 
Calcium addition ( -log M ) 
0"2 
0"1 
o 
Fig.l. Resolution of PKC subspecies purified from bovine 
cerebellum, and their calcium, phospholipid and diacylglycerol 
sensitivity. (A) A mixture of PKC subspecies purified from 
bovine cerebellum was resolved into three distinct fractions 
upon hydroxyapatite column chromatography, as described in 
section 2. Based on a number of criteria (see text), the identity 
of each peak was established as shown. Protein kinase activity 
was assayed for each column fraction (20 ~1 sample) in the 
presence of 8pg/ml PtdSer, 0.8/~g/ml DO and 0.3 mM 
calcium chloride (e) or in the presence of 0.5 mM EGTA (o), 
as described in section 2. (B) For each enzyme subspecies, 
protein kinase activity was assayed in the presence of 0.8/Lg/ml 
DO (o), 8/~g/ml PtdSer (A) or both lipids (e), at various 
concentrations of calcium chloride, as described in section 2. 
Where indicated with arrows, 0.5 mM EGTA was added 
instead of calcium chloride. Data are expressed as a percentage 
of the maximal activity obtained for each subspecies in the 
presence of 8/zg/ml PtdSer, 0.8/zg/ml DO and 0.3 mM 
calcium chloride (= 100%), and are the mean value of three or 
more separate determinations. 
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zyme. In bovine tissue the relative activity of the 
three peaks is a little different from that of the lat- 
ter tissues, with an enrichment of both 7- and a- 
PKC, and a less prominent B-PKC (a/~'/7, 
42" 17 : 41%, respectively; mean of four separate 
enzyme preparations). Immunoblotting analysis 
with polyclonal antibodies raised against C- 
terminal (V5 region) peptide sequences of the/?I- 
and BII-subspecies [7,10], gave an estimate of their 
ratio in the type II fraction from bovine cerebellum 
as 23 : 77%, respectively, which is identical to that 
of the rat cerebellum enzymes [7]. 
In the presence of PtdSer, all three enzyme 
subspecies showed an increase in protein kinase ac- 
tivity that was dependent on the calcium concen- 
tration in the assay (fig.lB). In the presence of 
PtdSer and DO, a shift to higher affinity in the 
calcium dose-response curves of approximately 
one order of magnitude for 7- and a-subspecies, 
and two to three orders of magnitude for the ~- 
subspecies was observed. In the presence of both 
cofactors, the ~'-subspecies showed considerable 
activity in the nominal absence of calcium. None 
of the enzymes were responsive to DO alone, at 
any calcium concentration. These properties are 
the same as those of the corresponding rat brain 
enzymes [ 12]. 
3.2. Activation by free fatty acids 
Micromolar concentrations of AA, in the 
absence of PtdSer and DO, selectively activates the 
7-subspecies of PKC (fig.2). In the presence o/" 
calcium (0.3 mM), activation of 7-PKC by AA 
(12.5/~M) exceeded 50% of the activity obtained in 
the presence of PtdSer, DO and calcium, whereas 
the ~- and a-subspecies were activated to less than 
10% of the maximal activity, at this concentration. 
These subspecies are known only to be responsive 
to high concentrations of AA (> 100/zM; [12]). A 
significant component of the activation of 7-PKC 
by AA was independent of calcium, as similarly 
described for the 7-subspecies from rat 
hypothalamus [13]. Calcium-independent ac iva- 
tion of PKC does not appear to be a general pro- 
perty of fatty acids, but is limited to AA and, 
possibly, other cis-unsaturated molecules, such as 
linoleic and oleic acid, which were found, 
however, to be relatively less active (fig.3). 
Saturated fatty acids, and the trans-isomer of oleic 
acid, elaidic acid, were practically inactive. 
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Fig.2. Arachidonic acid activation of PKC subspecies i olated 
from bovine cerebellum. Samples (20/A) of  type I(7), type 
II(~I/~'II) and type III(ot) PKC subspecies were assayed 
following the addition of increasing concentrations of AA 
(0-50/zM) either in the presence of  0.3 mM calcium chloride 
(e), or with 0.5 mM EGTA (o), as described in section 2. Data 
are expressed as a percentage of the maximal activity obtained 
for each subspecies in the presence of 8/~g/ml PtdSer, 
0.8/~g/ml DO and 0.3 mM calcium chloride ( = 100070), and are 
the mean value of two or more separate determinations. 
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Fig.3. Calcium-independent ac ivation of  7-PKC from bovine 
cerebellum by free fatty acids. Samples of 7-PKC (20/zl) were 
assayed with the fatty acids indicated, at a concentration of 
12/~M, in the absence of  PtdSer and DO, with 0.5 mM EGTA, 
as described in section 2. The response to 8/zg/ml PtdSer and 
0.8/zg/ml DO is also shown. Data are expressed as percentage 
activity relative to that obtained with AA ( = 100070), and are the 
mean value of  two or more separate determinations. 
3.3. Activation by arachidonic acid metabolites 
Fig.4 shows the ability of some AA metabolites, 
produced either by the cyclooxygenase (PGE2, 
TxB2) or lipoxygenase (5-HETE, 12-HETE, LTC4, 
LxA) pathways to support he activation of 7-type 
PKC in the absence of phospholipid, 
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Fig.4. Calcium-independent ac ivation of T-PKC from bovine 
cerebellum by various arachidonic a id metabolites. Samples of 
7-PKC (20/~l) were assayed with the AA metabolites indicated, 
in the absence of PtdSer and DO, with 0.5 mM I~GTA, as 
described insection 2. Each compound was tested at 0.125, 1.25 
and 12.5/~M, and the data for the most effective dose are given. 
The response to 8/~g/ml PtdSer and 0.8/~g/ml DO is also 
shown. Data are expressed aspercentage activity relative to that 
obtained with AA ( = 100°70), and are the mean value of two or 
more separate determinations. 
diacylglycerol and calcium. At equivalent concen- 
trations, LxA (5(S),6(R),15(S)-ll-cis-isomer) was
found to be more effective than AA itself (189°70 
activity relative to AA), and 12-HETE could also 
Table 1 
Activation of bovine cerebellum PKC subspecies by arachidonic 
acid metabolites 
°70 maximal response 
I (T)  II(~I/BII) III(t~) 
Calcium addition: - + - + - + 
AA (2.5) 6 4 2 3 1 2 
(12.5) 18 45 4 7 1 4 
LxA (2.5) 15 63 4 20 0 1 
(12.5) 34 91 4 23 0 1 
12-HETE (1.25) 9 15 3 0 2 3 
(12.5) 10 23 1 0 2 4 
Samples of each PKC subspecies (20/A) were incubated with 
AA, LxA or 12-HETE, at the concentrations indicated, in the 
absence of PtdSer and DO, and in the presence of either 
0.5 mM EGTA or 0.3 mM calcium chloride, as described in 
section 2. Data are expressed as a percent.age of the maximal 
activity obtained in the presence of 8 ~g/ml PtdSer, 0.8/~g/ml 
DO and 0.3 mM calcium chloride (= 100o70), and are the mean 
value of two or more separate determinations 
partially mimic AA (56°70 activity). LTC4, PGE2, 
5-HETE and TxB2 were essentially inactive at the 
range of concentrations tested (0.125-12.5/zM). 
The selectivity of activation by LxA and 12-HETE 
for the different PKC subspecies i shown in table 
1. As reported for AA (fig.2), both LxA and 
12-HETE (12.5/~M) showed poor activation of the 
a-  and/]-subspecies. Activation of the y-subspecies 
by LxA was enhanced by the presence of calcium 
(0.3 mM), such that, at the higher concentration, 
LxA could activate the y-PKC to approx. 90O7o f 
the maximal activity obtained in the presence of 
PtdSer, DO and calcium. 
4. DISCUSSION 
The present studies demonstrate that, at 
micromolar concentrations, cis-unsaturated fatty 
acids, particularly AA, activate directly, in the 
absence of phospholipid and diacylglycerol, only 
the y-subspecies of PKC from bovine cerebellum. 
Under the same conditions, two lipoxygenase 
metabolites of AA, LxA and 12-HETE, were also 
found to promote the selective activation of 7- 
PKC. In each case, a large component of this ac- 
tivation occurs independently of calcium. 
Previous reports have described that un- 
saturated fatty acids, or AA and some of its 
metabolites activate PKC in human neutrophils 
[14], human placenta cytosol [15] and rat brain 
[16]. These studies differ from the present report in 
that a mixture of PKC subspecies was employed, 
y-PKC being absent in neutrophils and placenta, 
and in general relatively high concentrations of fat- 
ty acid (> 100/zM) were necessary for significant 
activation. As reported here, and in previous 
studies from this laboratory [12,13], this would 
lead to activation of the o~- and/~-subspecies, but 
have little effect on the y-subspecies of PKC, if it 
were present. Methyl esters of LxA [15] were 
found to be much less active than the parent free 
acids, implying the importance of the carboxylic 
acid group. 
Although it has been established that PKC 
subspecies, particularly the y-type, are responsive 
to low concentrations of AA and LxA in in vitro 
experiments, evidence for a direct activation of 
PKC by these molecules under physiological situa- 
tions is lacking at present. 5- and 12-HETE, and 
12-HPETE (hydroperoxy derivative) have been 
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reported to participate in pre-synaptic nhibition of 
Aplysia sensory neurones [17], and recently, 
agonist binding to post-synaptic NMDA receptors 
was shown to stimulate the release of AA, 
l l -HETE and 12-HETE, from striatal neurones, 
probably by activation of PLA2 [18]. In an 
analogous manner to the 'transcellular' meta- 
bolism of eicosanoids that takes place during 
platelet-neutrophil interaction [ 19], these 
derivatives could be retroactive 'transsynaptic' 
messenger molecules, acting to modify pre- 
synaptic function. Certainly, their ability to pass 
easily through the cytosolic and membrane" com- 
partments of the cell makes them attractive can- 
didates for such a role. Based on some recent 
reports, a role for AA and its metabolites in synap- 
tic responses in the hippocampus can also be in- 
ferred. Induction of LTP in the presence of 
millimolar calcium, following tetanic stimulation 
of afferent neurones and NMDA receptor activa- 
tion, has been shown to be greatly reduced by the 
lipoxygenase inhibitor nordihydroguaiaretic a id 
[20], and inhibition of the time course of the per- 
sistent LTP response in rat hippocampus, as a 
result of a blockade of the PLA2 enzyme by 
mepacrine, has been reported to be reversed by ap- 
plication of the cis-unsaturated fatty acid oleate 
([21], but see [20]). Although there is both 
biochemical and electrophysiological evidence im- 
plicating the involvement of PKC at some stage(s) 
of the generation of LTP, its exact role is still 
obscure, as many of the proposed mechanisms are 
contentious. The involvement of AA or its lipox- 
ygenase metabolites as activators of y-PKC is an 
intriguing possibility, but provides yet a further 
source of conjecture. Interestingly, hippocampal 
pyramidal cells have been shown to stain heavily 
with antibodies against the y-subspecies of PKC, 
whereas pre-synaptic omponents appear not to 
express this subspecies [9]. 
From our studies of the differential expression 
of PKC subspecies in central nervous tissues [7], 
we found that y-PKC was isolated predominantly 
in the cytosolic fraction. It could be speculated 
that the function of AA and/or  its lipoxygenase 
metabolites, uch as LxA, is either to activate the 
soluble form of the y-type enzyme, independent of 
the hydrolysis of polyphosphoinositides (for exam- 
ple, during its release following activation of the 
phospholipase Al-lysophospholipase pathway 
[22]), or to reinforce activation of the membrane- 
bound form of the enzyme by diacylglycerol, 
following its release by the calcium-dependent 
PLA2, thereby increasing the effectiveness of the 
signal and the potential range of substrates. In this 
way, the nature of the activator may play a part in 
determining the substrate specificity of the en- 
zyme. The existence of such pathways, and their 
relative contribution to activation of the brain y- 
subspecies of PKC is an important aspect of future 
research. 
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